[Results of treatment following stage-dependent therapy of non-seminomatous testicular tumors].
The results of the treatment of 194 patients with non-seminomas were analyzed and statistically registered. The therapeutic approach is described and the cumulative probability of survival is compared according to the stages. For the total number of these tumours a cumulative 5-year-survival probability of 68.6% was calculated. In detail it reaches from 100% in clinical stage I to 39.7% in clinical stage III. The decisive change of the prognosis is between the clinical stages IIb and IIc. An adjuvant cytostatic therapy should, if performed, be aggressive. Relapses in the clinical stage I are possible and call for a critical valuation of the primary stage. A retarded cytostatic polychemotherapy should be performed only under certain conditions.
Tschochner
H J
HJ
Urologische Klinik Weidenplan, Bezirkskrankenhauses Halle/S.
Bockhorn
V
V
John
H
H
Katenkamp
D
D
Kühnert
M
M
Möller
A
A
Müller
H J
HJ
Ruffert
K
K
Stadie
G
G
Stiller
D
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery*
Behandlungsergebnisse nach stadiengerechter Therapie nichtseminatöser Hodentumoren.